Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Alto Neuroscience, Inc. ( (ANRO) ) has issued an announcement.
On May 13, 2025, Alto Neuroscience held its annual meeting of stockholders, where two key proposals were approved: the election of a Class I director and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2025. Additionally, Alto reported its first-quarter financial results for 2025, highlighting significant progress in its clinical trials. The company is on track with its Phase 2 trials for ALTO-203 in major depressive disorder and ALTO-101 in schizophrenia, with data expected later in 2025. Alto’s strong cash position is expected to support operations into 2028, reinforcing its leadership in targeted neuropsychiatric drug development.
The most recent analyst rating on (ANRO) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock, see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
Alto Neuroscience, Inc. faces significant financial challenges with zero revenue, increasing losses, and negative cash flows, reflecting in a low financial performance score. Despite some technical indicators suggesting short-term upward momentum, the stock’s valuation remains risky due to a negative P/E ratio and lack of dividends, resulting in an overall low stock score.
To see Spark’s full report on ANRO stock, click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders. The company emphasizes a biomarker-driven approach to patient stratification and is advancing several late-stage programs in its pipeline, including treatments for major depressive disorder, bipolar depression, and cognitive impairment associated with schizophrenia.
Average Trading Volume: 313,128
Technical Sentiment Signal: Sell
Current Market Cap: $63.35M
See more data about ANRO stock on TipRanks’ Stock Analysis page.